Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAF: Bevacizumab-800CW Imaging in Wet AMD
NCT05262244Phase 1Completed
- Sponsor
- University Medical Center Groningen
- Start
- Oct 2022
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bevacizumab-IRDye800CW in exudative macular degeneration, sponsored by University Medical Center Groningen. Primary endpoints: Safety of bevacizumab-800CW at 96 hours and Feasibility of fluorescence imaging at 96 hours. Started Oct 2022; status: completed.
02
Drugs
bevacizumab-IRDye800CW
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT05262244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05262244.